GlassScriptPhysician profile
Justin T Roach
NPI 1851950364
$446.66
in general payments reported to CMS, 2019-2025
15 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $301 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $81.41 | 2024-2025 | Caplyta |
| Abbvie INC. | $66.34 | 2024-2025 | |
| Organon LLC | $53.21 | 2024 | |
| Lilly USA, LLC | $46.08 | 2024 | Mounjaro, Zepbound |
| Eisai INC. | $37.41 | 2024 | |
| Phathom Pharmaceuticals, INC. | $20.70 | 2024 | Voquezna |
| Amgen INC. | $18.14 | 2024 | Repatha, Otezla |
| Otsuka America Pharmaceutical, INC. | $17.78 | 2025 | Abilify Maintena, Abilify Asimtufii |
| E.R. Squibb & Sons, L.L.C. | $17.24 | 2025 | Cobenfy |
| Viatris Specialty LLC | $15.23 | 2025 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.07 | 2024 | Xifaxan |
| Vanda Pharmaceuticals INC. | $14.86 | 2025 | Fanapt, Hetlioz |
| Alkermes, INC. | $14.42 | 2025 | Aristada, Lybalvi |
| Novartis Pharmaceuticals Corporation | $14.39 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $14.38 | 2024 | Breztri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.